Objective:To observe the clinical effect of Dengzhan Shengmai Capsule combined with conventional therapy on coronary atherosclerotic heart disease (hereinafter referred to as “coronary heart disease”) with hyperlipidemia (qi deficiency and blood stasis syndrome). MethodsNinety patients with coronary heart disease (CHD) accompanied with hyperlipidemia (qi deficiency and blood stasis syndrome) were randomly divided into control group and observation group, 45 cases in each group. The control group was given basic conventional therapy, while the observation group was also given Dengzhan Shengmai Capsule besides the conventional therapy. The course of treatment was 2 months in both groups. The clinical efficacy was observed and the level changes of serum homocysteine (Hcy), high sensitivity C-reactive protein (hs-CRP), blood lipid and TCM syndrome scores were compared.  Results:①The total effective rates of the observation group and the control group were 88.9% and 57.8%, respectively, and the clinical efficacy of the observation group was better than that of the control group (P<0.05). ②The total score of TCM syndromes and the score of each sub-item in the two groups decreased after treatment (P<0.05). The total score of TCM syndromes and the score of each sub-item in the observation group were lower than those in the control group (P<0.05). ③The frequency and duration of angina attacks decreased in both groups after treatment (P<0.05). Compared with the control group after treatment, the observation group had less frequency of angina attacks and shorter duration of angina attacks (P<0.05). ④There were significant differences in levels of Hcy, hs-CRP, TG, LDL-C and HDL-C in the observation group before and after treatment (P<0.05), while there were significant differences in levels of hs-CRP, TG, LDL-C and HDL-C in the control group before and after treatment (P<0.05). After treatment, the differences in levels of Hcy, hs-CRP, TG, LDL-C and HDL-C between two groups were significant (P<0.05). ⑤No significant adverse reactions occurred in both groups.  Conclusion:Compared with conventional therapy alone, Dengzhan Shengmai Capsule is effective in treating coronary heart disease with hyperlipidemia (qi deficiency and blood stasis syndrome), which can significantly improve angina symptoms and inflammatory state of patients and regulate blood lipid level.